News|Articles|May 20, 2026

What Patients Should Look Forward to at ASCO 2026

Name: What Patients Should Look Forward to at ASCO 2026
Uploaded: 2026-05-20T21:00:00Z
Duration: 10 min 5 s
Description: ASCO 2026 will highlight biomarker-driven lung cancer care, targeted therapies, ADCs and phase 3 trials shaping precision oncology advances.

Author(s)Spencer Feldman

Fact checked by: CURE staff

ASCO 2026 will highlight biomarker-driven lung cancer care, targeted therapies, ADCs and phase 3 trials shaping precision oncology advances.

Dr. Josh K. Sabari, a thoracic medical oncologist at NYU Langone’s Perlmutter Cancer Center and editor-in-chief of CURE, discussed the most anticipated lung cancer data expected at the 2026 ASCO Annual Meeting in an interview with CURE, highlighting biomarker-driven care, targeted therapies and expanding treatment modalities across solid tumors.